Pedro R Cutillas
Overview
Explore the profile of Pedro R Cutillas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
5292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Casado P, Marfa S, Hadi M, Gerdes H, Martin-Guerrero S, Miraki-Moud F, et al.
Cell Commun Signal
. 2025 Mar;
23(1):135.
PMID: 40082888
Background: The P21 activated kinases (PAK) are frequently dysregulated in cancer and have central roles in oncogenic signalling, prompting the development of PAK inhibitors (PAKi) as anticancer agents. However, such...
2.
Martin-Guerrero S, Martin-Estebane M, Lara Ordonez A, Canovas M, Martin-Oliva D, Gonzalez-Maeso J, et al.
Mol Psychiatry
. 2025 Feb;
PMID: 39900676
Alterations induced by maternal immune activation (MIA) during gestation impact the subsequent neurodevelopment of progeny, a process that in humans, has been linked to the development of several neuropsychiatric conditions....
3.
Burggraef M, Oxley A, Zaidi N, Cutillas P, Gaffney P, Livingston A
Nat Commun
. 2024 Nov;
15(1):9814.
PMID: 39537591
PEGylation (the covalent attachment of one or more poly(ethylene glycol) (PEG) units to a therapeutic) is a well-established technique in the pharmaceutical industry to increase blood-residence time and decrease immunogenicity....
4.
Borek W, Nobre L, Pedicona S, Campbell A, Christopher J, Nawaz N, et al.
EBioMedicine
. 2024 Sep;
108:105316.
PMID: 39293215
Background: Acute myeloid leukaemia (AML) is a bone marrow malignancy with poor prognosis. One of several treatments for AML is midostaurin combined with intensive chemotherapy (MIC), currently approved for FLT3...
5.
Conduit S, Pearce W, Bhamra A, Bilanges B, Bozal-Basterra L, Foukas L, et al.
Nat Commun
. 2024 Aug;
15(1):7181.
PMID: 39168978
Primary cilia are antenna-like organelles which sense extracellular cues and act as signalling hubs. Cilia dysfunction causes a heterogeneous group of disorders known as ciliopathy syndromes affecting most organs. Cilia...
6.
Martin-Guerrero S, Martin-Estebane M, Lara Ordonez A, Canovas M, Martin-Oliva D, Gonzalez-Maeso J, et al.
bioRxiv
. 2024 Jun;
PMID: 38895311
Alterations induced by maternal immune activation (MIA) during gestation impact the subsequent neurodevelopment of progeny, a process that in humans, has been linked to the development of several neuropsychiatric conditions....
7.
Hirani P, McDermott J, Rajeeve V, Cutillas P, Jones J, Pennington D, et al.
Cancer Res Commun
. 2024 Mar;
4(4):970-985.
PMID: 38517140
Significance: The response to immunotherapy has been poor toward solid tumors despite immune cells infiltrating into the tumor. The ECM has been associated with impacting T-cell infiltration toward the tumor...
8.
Branson N, Cutillas P, Bessant C
Bioinform Adv
. 2024 Jan;
4(1):vbad190.
PMID: 38282976
Motivation: Anti-cancer drug response prediction is a central problem within stratified medicine. Transcriptomic profiles of cancer cell lines are typically used for drug response prediction, but we hypothesize that proteomics...
9.
Yang M, Zhou X, Pearce S, Yang Z, Chen Q, Niu K, et al.
Arterioscler Thromb Vasc Biol
. 2023 Aug;
43(10):1900-1920.
PMID: 37589142
Background: Thoracic aortic dissection (TAD) is a life-threatening aortic disease without effective medical treatment. Increasing evidence has suggested a role for NE (neutrophil elastase) in vascular diseases. In this study,...
10.
Kassuhn W, Cutillas P, Kessler M, Sehouli J, Braicu E, Bluthgen N, et al.
Cancers (Basel)
. 2023 Jun;
15(12).
PMID: 37370765
Background: Tumour heterogeneity in high-grade serous ovarian cancer (HGSOC) is a proposed cause of acquired resistance to treatment and high rates of relapse. Among the four distinct molecular subtypes of...